Navigation Links
Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
Date:8/16/2011

ATLANTA, Aug. 16, 2011 /PRNewswire/ -- Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001.  IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).  This proof-of-concept trial will be conducted in multiple sclerosis (MS) patients on natalizumab (TYSABRI®), a patient group that is at significant risk for developing the potentially fatal PML disease.  JCV progresses to PML only in patients with chronic or drug-induced immune suppression, to include patients diagnosed with clinical AIDS or who are receiving monoclonal antibody treatment for MS, lupus, rheumatoid arthritis, leukemia or lymphoma.

(Logo: http://photos.prnewswire.com/prnh/20110517/CL02791LOGO)

The Phase II trial will be a four-week, open-label, sequential-dose-ranging study of the compound's safety and its antiviral effects against JCV in 48 patients with a relapsing form of MS who receive TYSABRI® infusion therapy.  In addition to closely monitoring the safety and pharmacokinetic profile of IkT-001, the study also will determine the potential antiviral effect of IkT-001 against JCV as measured by the suppression of urinary excretion of JCV.  Led by Jeffrey English, MD, of the Multiple Sclerosis Center of Atlanta, the study will be performed at three to five U.S. treatment centers for MS. All participating centers must be registered with the TOUCH Program for the prescription and infusion of TYSABRI® to patients with MS.

"The launch of this study is a pivotal event for Inhibikase Therapeutics, just 23 months into operations, as we advance a new approach to treating bacterial and viral infectious diseases into the clinic," said Milton H. Werner Ph.D., Chief Executive Officer and
'/>"/>

SOURCE Inhibikase Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
2. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Laboratories, Inc. (Nasdaq: CBRX ) ("Columbia" ... the three and six-month periods ended June 30, ... from the contribution of the Molecular Profiles services ... an anticipated and temporary decline in product revenues ... in one high-volume, high-margin market. Throughout the renewal ...
(Date:7/31/2014)... 31, 2014 Auxilium Pharmaceuticals, Inc. ... biopharmaceutical company, today announced that the Company will ... its partner Asahi Kasei Pharma Corporation (Asahi Kasei). ... submission of a regulatory application to the Japanese ... ® (collagenase clostridium histolyticum) for the treatment ...
(Date:7/30/2014)...  There is still time to share your ... Annual Institute for Supply Management ® – ... Management is open for submissions.  The annual competition ... of supply management by recognizing supply management organizations ... practices.  Entries are due August 22, 2014. ...
Breaking Medicine Technology:Columbia Laboratories Reports Second Quarter 2014 Financial Results 2Columbia Laboratories Reports Second Quarter 2014 Financial Results 3Columbia Laboratories Reports Second Quarter 2014 Financial Results 4Columbia Laboratories Reports Second Quarter 2014 Financial Results 5Columbia Laboratories Reports Second Quarter 2014 Financial Results 6Columbia Laboratories Reports Second Quarter 2014 Financial Results 7Columbia Laboratories Reports Second Quarter 2014 Financial Results 8Columbia Laboratories Reports Second Quarter 2014 Financial Results 9Columbia Laboratories Reports Second Quarter 2014 Financial Results 10Columbia Laboratories Reports Second Quarter 2014 Financial Results 11Columbia Laboratories Reports Second Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Milestone: Partner Asahi Kasei Pharma Corporation Completes Regulatory Submission For Dupuytren's Contracture In Japan 5Institute for Supply Management, Michigan State University to recognize companies with excellent supply management practices 2
... Ltd. is pleased to announce that the Phase 2a clinical ... completed by January 21, 2011. Our company focuses ... market of androgenetic alopecia treatment and has developed a new ... androgenetic alopecia treatment was performed in 48 patients with mild-to-moderate ...
... 21, 2011 Cardiac Science Corporation , a ... and diagnostic cardiac monitoring devices that connect ... information systems, today announced it has completed certification with ... its HeartCentrix cardiology device connectivity solution for its resting ...
Cached Medicine Technology:R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia 2R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 2Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 3Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 4Cardiac Science Extends Device Connectivity to Allscripts Professional™ Electronic Health Record 5
(Date:7/31/2014)... 2014 Many lawyers take up the law ... correct injustices, and preserve the rule of law. Upholding these ... lauded as crusading and exemplary by some, but reckless and ... whose seed might be planted within the legal system itself, ... punishment for an attorney - a referral to the bar's ...
(Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... managed IT solutions firm based in New York City, ... cabling infrastructure for the midtown Manhattan headquarters of a ... in corporate and investment banking. , Chico Ramnarayan, Chief ... with our client is an opportunity for us to ...
(Date:7/31/2014)... Loffler Companies, the leading business technology and services ... as a Microsoft Community Connections Partner of the Year ... 2014. , The Microsoft U.S. SMB Champions Club ... IT services and solutions to small and midsized business ... Champions Club member, Loffler has established a proven track ...
(Date:7/31/2014)... According to new research report "Meat Substitutes Market ... Tofu-Based Product, Tempeh, TVP, Seitan, Quorn, Others), by ... to 2019", defines and segments the global Meat ... the market value of sources, types, and categories ... driving and restraining factors for the global market ...
(Date:7/31/2014)... Angeles, California (PRWEB) July 31, 2014 ... program all year round to CEO Belina Calderon’s ... employment services and medical billing, 1Heart Caregiver Services, ... 1Heart Business Academy applauds the most recent resource ... Commerce Ambassador Glenn Bowie for sharing his expertise ...
Breaking Medicine News(10 mins):Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 3Health News:Global Bank Awards CRA with Network Infrastructure Contract 2Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 2Health News:Loffler Companies Named Microsoft Community Connections Partner of the Year Award Winner 3Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 2Health News:Meat Substitutes Market Worth $4,622.4 Million by 2019 - New Report by MarketsandMarkets 3Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 2Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 3Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 4
... people with history of unprotected sex to have an ... transmission.// The announcement being the first case of such ... Thursday uncovered two clusters of HIV infections, HIV-1 subtype ... government scientists. They said that both the clusters found ...
... and China's growing strengths in medical research, British Prime ... 'global medical excellence cluster' comprising universities and drugs companies. ... southeast England to protect Britain's science base and boost ... latest of measures initiated by government functionaries while citing ...
... detection of colorectal cancer were almost four times as successful ... they// were more likely to spot polyps, according to ... a thin flexible tube with a tiny camera into the ... for abnormalities, including cancerous and pre-cancerous growths. ,On ...
... anti-rejection medications for kidney transplant recipients. It is well ... ,Long-term steroid use is associated with bone ... Therefore, much effort has been made toward decreasing, withdrawing ... organ transplantation. ,A new study in Clinical ...
... drivers suspected of driving while ‘over the limit,’ but subsequently ... tested positive// for a range of drugs, reveals research in ... call for routine drugs testing in all drivers who are ... ,The researchers base their findings on 2000 blood and urine ...
... Medicine and EXACT Sciences Corporation announced today the publication// ... DNA testing. The study found that the test demonstrated ... detection across all stages of cancer, regardless of the ... study confirms that stool-based DNA technologies can achieve high ...
Cached Medicine News:Health News:Britain Plans Medical Hub To Meet India, China Challenge 2Health News:Colonoscopies Can Help Prevent Colon Cancer; Only When Done Properly 2Health News:One in Three Drivers Under ‘The Limit’ for Alcohol Still Test Positive for Dru 2Health News:Study Results on Stool DNA Testing for Colon Cancer Announced 2
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is ... a method for safe, simple catheterization ... urinary tract infections. It includes ... The new EasyOff tear tab ...
... Self-Cath Closed System is a latex-free ... for safe, simple catheterization designed to ... infections. It includes a 100% ... new EasyOff tear tab makes it ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
Medicine Products: